See All Clinical Studies

Assessing a Dose‐Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients

The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like protein) in
the urine that is changed after treatment of hydralazine.

 

Intervention/Treatment: Drug: Hydralazine

Participants will be asked to take pills two times per day for 6 weeks. This is a dose increasing study with potential doses ranging from 5 mg two times per day to 50 mg two times per day.

 

Study Arms: Experimental: Group 1: Hydralazine

Participants will take hydralazine twice daily for total of 6 weeks. The dose of hydralazine will be increased every 2 weeks.

Intervention: Drug: Hydralazine

 

Participation Criteria:
Inclusion Criteria:
● Confirmed diagnosis of ADPKD
● estimated glomerular filtration rate (eGFR) > 60 ml/min/1.73m^2

Exclusion Criteria:
● History of systemic lupus erythematous or other rheumatologic disorder
● Baseline anti-nuclear antibody (ANA) >1:80 for females and >1:40 for males
● Blood pressure < 120/80 without anti-hypertensive
● Angina pectoris or myocardial infarction in the last 6 months
● Liver disease
● Allergy to hydralazine

 

Contact Information:
Debbie Griffin, RN
913-588-7691
dgriffin3@kumc.edu

 

Study being conducted in Kansas
Location Detail
University of Kansas Medical Center
Age range: 18-65
Stage: Recruiting
Status: Active
Phase:
LEARN MORE